News FocusBiotechnology

Stem Cells Lose Market Luster

See allHide authors and affiliations

Science  21 Mar 2003:
Vol. 299, Issue 5614, pp. 1830-1831
DOI: 10.1126/science.299.5614.1830

You are currently viewing the summary.

View Full Text

Summary

The stock market slump and subsequent evaporation of venture capital is being felt keenly across the biotech landscape. Hit particularly hard is one of the hottest areas of all: human embryonic stem cells and therapeutic cloning, the creation of stem cell lines that are identical genetically to a prospective patient's. The depth of suffering among stem cell companies reflects how far off profits may lie.